GLP-1 receptor agonists in the regulation of the brain–metabolism axis: implications for mental health
DOI:
https://doi.org/10.12775/JEHS.2026.91.70804Keywords
GLP-1 receptor agonists, mental health, depression, addiction, cognition, psychiatric safetyAbstract
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used in the treatment of type 2 diabetes and obesity, have recently gained attention for their potential effects on the central nervous system and mental health, particularly within the metabolic–brain axis linking metabolic and neuropsychiatric processes.
Aim: The aim of this study was to review the current evidence on the effects of GLP-1RAs on mental health, with particular focus on depression, cognitive function, substance use disorders, and psychiatric safety.
Material and methods: A narrative review was conducted based on a targeted selection of review articles, including systematic reviews, meta-analyses, and comprehensive reviews identified in the PubMed/MEDLINE database; publications from the last five years were included using predefined inclusion and exclusion criteria, and the analysis focused on synthesizing the most clinically relevant findings.
Results: GLP-1RAs may affect mental health through dopaminergic reward pathways, the HPA axis, and neuroinflammation. Meta-analyses show a small but significant reduction in depressive symptoms, and these drugs may also reduce addictive behaviors and improve eating patterns and cognitive function. Large-scale studies confirm a favorable psychiatric safety profile with no increased risk of adverse psychiatric events.
Conclusions: GLP-1 receptor agonists show promise for mental health beyond their metabolic role, particularly for mood disorders and addiction. However, well-designed clinical studies are still needed to clarify the clinical relevance, durability, and practical applicability of these effects.
References
1. Sa B, Maristany A, Subramaniam A, Guillen R, Buonocore B, Smith A, Oldak SE, Padilla V. Psychiatric effects of GLP-1 receptor agonists: a systematic review of emerging evidence. Diabetes Obes Metab. 2025;28(1):50-59. https://doi.org/10.1111/dom.70198
2. Kim J. Glucagon-like peptide-1 receptor agonists and mental health: a narrative review of emerging benefits and risks. J Yeungnam Med Sci. 2025;42:61. https://doi.org/10.12701/jyms.2025.42.61
3. Glucagon-Like Peptide-1 Receptor Agonists and Mental Health, Cognition, and Quality of Life: meta-analysis of randomized placebo-controlled trials. [Journal information pending in PubMed]. PMID: 40366681. doi: 10.1001/jamapsychiatry.2025.0679.
4. Efficacy of GLP-1 agonists in psychiatric illnesses: a scoping review. [Journal information pending in PubMed]. 2025. https://doi.org/10.4088/PCC.24nr03828
5. Chen X, Zhao P, Wang W, Guo L, Pan Q. The antidepressant effects of GLP-1 receptor agonists: a systematic review and meta-analysis. Am J Geriatr Psychiatry. 2024;32(1):117-127. https://pubmed.ncbi.nlm.nih.gov/37684186/
6. GLP-1 receptor agonists and incident depression risk: a systematic review. [Journal information pending in PubMed]. 2023. PMID: 37331261. DOI: 10.1016/j.jagp.2023.08.010
7. Potential role of GLP-1 receptor agonists in substance use disorders. [Journal information pending in PubMed]. PMID: 39288591. https://doi.org/10.1016/j.jpsychires.2023.05.041
8. GLP-1 receptor agonists: promising therapeutic targets in alcohol use disorder and other addiction-related outcomes. [Journal information pending in PubMed]. 2025. PMID: 39980336. https://doi.org/10.1210/endocr/bqaf028
9. Glucagon-like peptide-1 receptor agonists and alcohol use disorder: a comprehensive review. [Journal information pending in PubMed]. PMID: 40364515. https://doi.org/10.1111/dom.16453
10. The effects of GLP-1 receptor agonists on alcohol consumption and craving: a systematic review and meta-analysis. 2026. PMID: 41350683. https://doi.org/10.1186/s13722-025-00637-z
11. Meshkat, S., Di Luciano, C., Swiderski, A., Li, G., Aguilar, R. J., Dunkley, B. T., Reichelt, A. C., Zhang, Y., Greenshaw, A., Vermetten, E., Jetly, R., Dash, S., Agarwal, S. M., Swainson, J., & Bhat, V. (2025). Efficacy and safety of glucagon-like peptide-1 agonists for psychiatric symptoms: A systematic review. Brain and Behavior, 15(7), e70661. https://doi.org/10.1002/brb3.70661
12. Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., Ismail, K., & Pillinger, T. (2025). Glucagon-like peptide 1 receptor agonists and mental health: A systematic review and meta-analysis. JAMA Psychiatry, 82(7), 643–653. https://doi.org/10.1001/jamapsychiatry.2025.0679
13. Arillotta, D., Floresta, G., Guirguis, A., Corkery, J. M., Catalani, V., Martinotti, G., Sensi, S. L., & Schifano, F. (2023). GLP-1 receptor agonists and related mental health issues: Insights from a range of social media platforms using a mixed-methods approach. Brain Sciences, 13(11), 1503. https://doi.org/10.3390/brainsci13111503
14. Ali, M., Ahmed, A., Khan, B. A., Shah, S. T., Naveed, S., & Ashraf, N. (2025). Efficacy of GLP-1 agonists in psychiatric illnesses: A scoping review. The Primary Care Companion for CNS Disorders, 27(3), 24nr03828. https://doi.org/10.4088/PCC.24nr03828
15. Srisurapanont, M., Suttajit, S., Likhitsathian, S., Suradom, C., & Maneeton, B. (2026). Glucagon-like peptide-1 receptor agonists in individuals with severe mental illness: A systematic review and meta-analysis of randomized controlled trials. International Journal of Psychiatry in Medicine. Advance online publication. https://doi.org/10.1177/00912174261422822
16. Li, S., Sabbah, S. G., Kwan, A. T. H., & McIntyre, R. S. (2025). Repurposing glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of depression: A systematic review of preclinical, observational and clinical investigations. European Neuropsychopharmacology, 99, 56–67. https://doi.org/10.1016/j.euroneuro.2025.08.002
17. Shen, M. R., Owusu-Boaitey, K., Holsen, L. M., & Suzuki, J. (2024). The efficacy of GLP-1 agonists in treating substance use disorder in patients: A scoping review. Journal of Addiction Medicine, 18(5), 488–498. https://doi.org/10.1097/ADM.0000000000001347
18. Müller Alves, K., Teixeira da Silva, M., Kramer, C. K., & Viana, L. V. (2025). GLP-1R agonists for weight loss in psychiatric disorders: A systematic review and meta-analysis. Journal of the Endocrine Society, 9(12), bvaf150. https://doi.org/10.1210/jendso/bvaf150
19. Gierlach, K., Nowak, K., Nowak, K., Olejarz, Z., Słowik, M., Drygała, Z., … Krasuska, M. (2024). Critical analysis of the efficacy and limitations of GLP-1 pharmaceuticals in obesity management: A comprehensive literature review. Journal of Education, Health and Sport, 55, 87–103. https://doi.org/10.12775/JEHS.2024.55.006
20. Wydeheft, L., Jusiak, J., Halik, P., Malon, P., & Kędziora-Kornatowska, K. (2026). GLP-1 agonists and dual agonists in obesity treatment: Benefits, risks, and clinical challenges in geriatric patients. Quality in Sport, 49, 67673. https://doi.org/10.12775/QS.2026.49.67673
21. Rychlica K, Gawin K, Zawiślak W, Ignasiak A, Cisowski M, Dąbrowska M, et al. Dietary modulation and clinical outcomes during GLP-1 receptor agonist therapy: a literature review. Quality in Sport. 2026;49:67649. https://doi.org/10.12775/QS.2026.49.67649
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Zuzanna Michalik, Zuzanna Kryś, Klaudia Kapelka, Zofia Bułka, Michał Chodor, Kacper Śliwiński, Karol Mirkowski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 6
Number of citations: 0
